ReleviumBio
ReleviumBio, based in Galway, Ireland, is a healthcare company focused on developing an injectable gel for treating knee osteoarthritis, with potential applications in other joints.
Company Overview
ReleviumBio, formerly known as Relevium, is a healthcare company based in Galway, County Galway, Ireland. With a small team of four, it operates within the therapeutics sub-industry, specifically focusing on innovative treatments for osteoarthritis. The company is part of the Y-Combinator S22 batch and primarily serves the regions of Ireland and Europe.
Therapeutics for Knee Osteoarthritis
ReleviumBio is developing an injectable gel designed to treat knee osteoarthritis. This biotherapeutic product offers significant pain relief by selectively blocking nerve transmission, with effects lasting four times longer than existing treatments. The treatment represents a substantial market opportunity in the US, as insurance currently covers $770 per six-monthly treatment, culminating in a potential $7.7 billion market.
Non-Dilutive Funding and Testing
ReleviumBio has secured $3.7 million in non-dilutive funding to advance its healthcare solutions. The company has completed preclinical testing of its injectable gel, demonstrating the drug's safety and efficacy. These tests indicate that the product provides long-lasting pain relief and effectively blocks nerves responsible for pain transmission.
Applications Beyond Knee Osteoarthritis
The platform biotherapeutic developed by ReleviumBio is not limited to treating knee osteoarthritis. It can also be adapted to treat other joints affected by osteoarthritis, such as the hip and ankle. This adaptability positions the company well for expanding its market reach within the field of osteoarthritis treatments.
